Boehringer and Eli Lilly have moved closer to a heart failure indication for their SGLT2 inhibitor Jardiance, as the FDA starts a fast-track review of the drug in its first use beyond diabetes. The US ...

Novo Nordisk's Rybelsus has become the first oral GLP-1 agonist to pick up a regulatory approval for cardiovascular risk reduction, after getting a green light from the EMA's human medicine committee.

Graduate School of Pharmaceutical Sciences, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba 260-8675, Japan, Molecular Imaging Center, National Institute of Radiological Sciences, Anagawa, Inage-ku, ...

Abstract: Cardiovascular disease (CVD) is a leading cause of global mortality, accounting for an estimated 17.9 million deaths annually. CVD is broadly defined as a group of medical conditions ...